Personalized management for monogenic diabetes using genetic screening

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to create a registry and management platform for patients with monogenic diabetes mellitus (MDM) through internet-based and mobile application software. Participants will register on the platform, undergo genetic screening to identify mutations causing MDM, and receive individualized management and monitoring for blood glucose control. The study seeks to understand the genetic landscape of MDM in China and evaluate the effectiveness and safety of this personalized approach in improving patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Diabetes patients who developed before 25 years old; Or they were diagnosed with diabetes before the age of 35, and two or more immediate relatives were diagnosed with diabetes before the age of 45;
2. Body mass index (BMI) at diagnosis \< 28 kg/m2;
3. Anti glutamic acid decarboxylase antibody (GAD Ab), anti islet cell antibody (ICA Ab), and anti insulin autoantibody (IAA Ab) were all negative;

Exclusion Criteria:

1. Secondary diabetes patients with other endocrine diseases, such as hyperthyroidism or hypothyroidism, hyperparathyroidism or hypothyroidism, acromegaly, Cushing's syndrome, autoimmune multiple endocrine diseases, etc.;
2. Systemic use of corticosteroids, immunosuppressants, and other drugs within the past 6 months;
3. Patients with malignant tumors.

Where it's running

• Tianjin Medical University General Hospital
  Tianjin, China Recruiting

Study contacts

• Study coordinator: Ming Liu
• Email: mingliu@tmu.edu.cn
• Phone: +86 183 2201 7516

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Chinese monogenic diabetes registry

  This project will test whether an online and mobile registry can find and genetically confirm people in China with monogenic forms of diabetes, including neonatal diabetes and MODY.

  Recruiting Tianjin Medical University General Hospital · Tianjin · NCT07492004

• Dorzagliatin for glucokinase (GCK-MODY) diabetes

  This trial will test whether dorzagliatin, a drug that activates glucokinase, can lower blood sugar in adults with GCK-MODY caused by an inactivating GCK mutation.

  Recruiting Phase 2 Chinese University of Hong Kong · Hong Kong · NCT06976658

• Understanding beta cell disorders through genetic insights

  This study is trying to learn more about beta cell problems, like diabetes, by looking at the genes of people with and without these issues to see if it can help find new treatments.

  Recruiting University of Exeter · Exeter, Devon · NCT06478121

• Identifying Monogenic Diabetes Misdiagnosed as Type 1

  This study is trying to find out how often young people are wrongly diagnosed with type 1 diabetes when they actually have a rare form called monogenic diabetes, by testing their blood and looking for specific genetic changes.

  Recruiting McGill University Health Centre/Research Institute of the McGill University Health Centre · Montreal, Quebec · NCT03988764

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.